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INTRODUCTION
High-dose oral busulfan (Bu) in combination with
cyclophosphamide (BuCy) or other cytotoxic agents is widely
used in pretransplantation conditioning therapy before
hematopoietic progenitor cell transplantation (HPCT).
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ABSTRACT
The unpredictable intestinal absorption and erratic bioavailability of oral busulfan (Bu) has limited the drug’s use in
high-dose pretransplantation conditioning therapy. To standardize drug delivery, we solubilized Bu for parenteral
use. This new intravenous (IV) Bu formulation was combined with oral Bu and cyclophosphamide (Cy) to evaluate
(1) the human acute toxicity of IV Bu and its solvent system and (2) the pharmacokinetics of Bu in patients undergo-
ing hematopoietic progenitor cell transplantation (HPCT). One dose of IV Bu (escalating from 0.08 to 0.8 mg/kg)
was given over 2 hours by pump; 6 hours later, an oral Bu regimen was begun, consisting of 1 mg/kg every 6 hours
for 15 doses, followed by Cy, 60 mg/kg daily for 2 days. After 1 day of rest, HPCT was performed. The IV Bu dose
was well tolerated and did not produce any acute toxicity reaction that could be attributed to the solvent system of
dimethylacetamide and polyethylene glycol (PEG)-400. All observed treatment-related toxicity was as would be
expected after high-dose oral Bu plus Cy. When the IV Bu was used as reference solution, the pharmacokinetic
analysis indicated an average bioavailability of oral high-dose Bu of 69%, ranging from <10% to virtually 100%. Fur-
ther, the 2-hour infusion of IV Bu gave a time to maximum plasma concentration following drug administration
similar to that of oral Bu (2 hours and 1.8 hours, respectively), and IV Bu had a clearance similar to that of oral Bu.
Based on the data in this study, we suggest that the optimal (starting) dose of IV Bu (in combination with Cy) in our
forthcoming phase 2 trial should be on the order of 0.8 mg/kg to target an area under the curve (AUC) of 1100 to
1200 µmol/L per minute. This would secure myeloablation and engraftment but save the vast majority of patients
from the increased risk of serious hepatic veno-occlusive disease that has been reported when the AUC level
exceeds 1500 µmol/L per minute. Bu administration via the IV route will assure complete bioavailability and reliable
systemic drug exposure with more predictable blood levels and, therefore, possibly lower the risks for serious/life-
threatening toxicity, graft rejection, and recurrent leukemia.
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Bu-based combinations are important alternatives to total
body radiation–based therapy, and numerous clinical trials
demonstrate their efﬁcacy [1-5]. Because of variable absorp-
tion of Bu in the gastrointestinal tract, there is unfortunately
marked interindividual variation in oral Bu pharmacology,
variations that may reach 10-fold or larger [6-15]. Interdose
variations in Bu bioavailability can also be signiﬁcant. Fur-
ther, vomiting after oral dosing frequently occurs, and factors
such as gastric pH may also affect intestinal drug absorption
[10,13-15].
The unpredictable pharmacology of Bu is important:
several investigators have reported that high Bu blood con-
centration-versus-time area under the curve (AUC) corre-
lates with serious side effects in the liver [6,16-18] and cen-
tral nervous system (CNS) [15,19], whereas low blood Bu
AUC levels have been connected with an increased risk for
graft rejection and recurrent leukemia after transplantation
[20,21]. To circumvent both the erratic, unpredictable
intestinal Bu absorption and the hepatic ﬁrst-pass effect that
might contribute to hepatic veno-occlusive disease (VOD)
[22], we developed a pharmaceutically acceptable parenteral
Bu formulation [23,24]. After testing the safety of this for-
mulation in a large-animal model [25], the current human
modiﬁed phase 1 trial was conducted. The objectives of this
study were (1) to determine whether Bu in the solvent sys-
tem consisting of dimethylacetamide (DMA) and polyethyl-
ene glycol (PEG)-400 (1:2, vol/vol) could be safely adminis-
tered in humans without acute toxicity from the solvent
vehicle and (2) to determine the IV Bu dose that would
achieve an AUC similar to that of oral Bu when the latter
was given at a dose of 1.0 mg/kg. This IV dose would be
used in our forthcoming phase 2 studies, in which all Bu
doses would be administered via the parenteral route.
PATIENTS AND METHODS
Patients
Patients with the following hematologic malignancies
were eligible for this study, provided that they did not qual-
ify for an institutional treatment protocol of higher priority:
(1) acute leukemia past first remission or refractory to
induction chemotherapy, (2) chronic myeloid leukemia past
first chronic phase, or (3) primary refractory or resistant
relapsed Hodgkin’s disease or non-Hodgkin’s lymphoma.
The eligibility criteria also included ages between 16 and
55 years (physiological age); normal renal and hepatic func-
tion (creatinine ≤1.5 mg/100 mL, bilirubin ≤1.0 mg/100 mL,
alanine transaminase <3 upper normal level); a cardiac left
ventricular ejection fraction of ≥50%; pulmonary function
tests, including forced expiratory volume in 1 second (FEV1)
and carbon monoxide diffusion capacity (DLCO) ≥50% of
predicted; negative serology for hepatitis and HIV infection;
and a life expectancy of at least 12 weeks. Patients were eligi-
ble for this study if either autologous or allogeneic pro-
genitor cells from an HLA-matched related donor were
available. In accordance with institutional guidelines, all
patients gave written informed consent before study entry.
Treatment Plan
The treatment was modiﬁed from Tutschka et al. [26]:
Bu was administered every 6 hours for a total of 16 doses
(days –7 to –4) followed by cyclophosphamide 60 mg/kg IV
over 1 hour on 2 consecutive days (days –3 and –2). The
first (IV) Bu dose (Busulfex Injection; Orphan Medical,
Minnetonka, MN) was diluted in normal saline or 5% dex-
trose in water (D5W) to 0.5 mg/mL and infused over 2 hours by
pump through a central venous catheter. The Busulfex solu-
tion diluted in either normal saline or D5W is stable for at
least 8 hours at room temperature; when diluted in normal
saline, it is stable for 12 hours if refrigerated [27]. An infu-
sion time of 2 hours was chosen to mimic the literature-
reported values, where the time of maximum plasma con-
centration following drug administration (Tmax) of Bu after
oral administration was reported to be on the order of 1 to
2 hours. The starting dose was 0.08 mg/kg body weight (the
lower of actual or ideal weight), based on the preclinical
safety data from the large-animal (beagle) model [25]. The
IV Bu dose was escalated to 0.2 mg/kg, then to 0.4 mg/kg,
and ﬁnally to 0.8 mg/kg in cohorts of 3 patients at each dose
level. At the ﬁnal level, 3 additional patients were treated to
conﬁrm the pharmacokinetic (PK) ﬁndings. Six hours after
the start of the IV Bu infusion, the patients began to receive
oral Bu at 1.0 mg/kg every 6 hours for 15 doses. Bone mar-
row or granulocyte colony-stimulating factor (G-CSF)–
stimulated blood progenitor cells were infused after a day of
rest. Prophylaxis against graft-versus-host disease was done
using cyclosporine A and low-dose methotrexate. Engraft-
ment was assessed by peripheral blood counts and marrow
examination. Adverse events were evaluated using the modi-
ﬁed National Cancer Institute (NCI) criteria.
Pharmacokinetics
Blood samples (5 mL) for PK analysis were collected in
heparinized tubes immediately before the administration of
IV Bu; at 15, 30, 45, and 115 minutes after the start of the
2-hour infusion; and at 15, 30, 60, 120, 180, and 240 min-
utes after the end of infusion. In addition, blood samples
were drawn immediately before and at 15, 30, 45, 60, 75, 90,
120, 240, and 360 minutes after administration of the ﬁfth
(fourth oral) Bu dose.
Samples were analyzed as previously described [28-30].
Brieﬂy, the blood samples were transported on ice to the lab-
oratory. Plasma was separated by centrifugation at 2500 rpm
for 10 minutes at 4°C within 1 hour, placed in cryogenic
vials, and stored at –40°C until analysis. All plasma samples
from each patient were thawed just before analysis and
deproteinated with acetonitrile, and the supernatant was
derivatized with 5% (wt/vol) diethyldithiocarbamate and
25 mmol/L ammonium acetate to 1,4-bis(diethyldithiocar-
bamoyl) butane. The derivatized Bu was extracted using a
3-step liquid-liquid extraction procedure with ethyl acetate,
and the resulting supernatant was slowly dried at 45°C under
a gentle nitrogen ﬂow. The samples were reconstituted with
100 µL methanol, and 50 µL was injected onto the high-per-
formance liquid chromatography (HPLC) system for analy-
sis, using a Waters model 717-Plus Autosampler (Waters,
Milford, MA). Separation was achieved by isocratic elution
using a mobile phase of methanol (80% vol/vol) in water, at a
flow rate of 1.0 mL/min (model 616 Pump + 600S Con-
troller; Waters). Busulfan was isolated using a C18 analytical
column and pre-column guard ﬁlter (Nova-Pak C18, 250 
4.6 mm, 4 µm particle size). The analytical column was
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maintained at an ambient temperature of 30°C. The column
effluent was monitored using a photodiode array detector
over wavelengths from 220 to 320 nm. A derived channel of
254 nm was extracted to create chromatograms for peak
analysis. The Bu peak was identiﬁed using ultraviolet (UV)
absorbance spectral analysis and retention time (Bu = 7.5
min), with Bu concentrations determined by a calibration
curve using external standardization.
No co-eluting peaks were observed in either standards
or patient samples. The interday and intraday coefﬁcients of
variation were less than 15%, with a lower limit of quantiﬁ-
cation of 50 ng/mL, and the detector response was linear for
extracted plasma samples containing up to 10 µg/mL of Bu.
Various compartmental models were ﬁt to each sample’s Bu
concentration-time data, using maximum likelihood estima-
tion and data weighed as 1/y2. Model selection was deter-
mined using Akiake’s information criteria [31], visual inspec-
tion, and statistical estimation of fit. The best fit of the
plasma-concentration-time data was observed with an open
2-compartment model for the IV drug data, whereas a
1-compartment model was adequate for the oral drug data.
Parameters such as volume of distribution of the central
compartment, elimination rate constant, and microconstants
were estimated, whereas steady-state volume of distribution,
t1/2, and clearance were calculated from the primary parame-
ters. After IV dosing, the recorded half-life was based on the
open 2-compartment model, and after oral dosing the ter-
minal half-life was recorded. The plasma concentration ver-
sus time AUC was calculated from the model-derived
parameters. The PK modeling was performed using
ADAPT II Software Version 4.0 (BMRS, University of
Southern California, Los Angeles, CA) [32].
RESULTS
The 15 patients treated on this protocol had advanced
hematologic malignancies: 10 patients had recurrent non-
Hodgkin’s lymphoma, 3 had Hodgkin’s disease, and 2 had
recurrent acute myeloid leukemia. There were 11 men and
4 women with a median age of 46 years (range, 19-58 years).
Two patients received allogeneic peripheral blood pro-
genitor cells (PBPCs) from tissue-compatible sibling
donors. The remaining (autologous) patients received
PBPC (11 patients), bone marrow (1 patient), or a combina-
tion of bone marrow and PBPC (1 patient).
Aside from minimal nausea, no acute side effects could
be attributed to the Bu or solvent system during the infusion
of the ﬁrst drug dose. The side-effect spectrum experienced
with the regimen paralleled what had been previously
described in patients preconditioned for HPCT with the
BuCy2 regimen when all 16 Bu doses were administered
orally [1-5,26]—ie, nausea, mild mucositis, and (in 2 cases)
mild to moderately severe hepatic VOD, which resolved
with conservative management in both patients. No patient
experienced neurologic toxicity. Engraftment (deﬁned as 0.5
 109 neutrophils/L) was recorded at a median of 12 days
(range, 10 to 25 days) for the 13 patients who had an autolo-
gous HPCT and at 8 and 15 days for the 2 patients who
received an allogeneic graft.
PK Analysis
Complete PK data, including data from both the IV and
the oral dose administrations, were available from only 10 of
the 15 patients treated in the study (Tables 1 and 2). One
patient vomited shortly after the ﬁfth (fourth oral) Bu dose.
He received a second oral dose to replace what was believed to
have been lost in the vomitus, but was considered inevaluable
for calculating the oral dose PK parameters because it was
impossible to determine the total amount of oral Bu that he
had received. This patient was analyzed only for acute toxic-
ity/clinical tolerance of the IV Bu dose and for calculating the
PK parameters after the IV dose. In addition, the data from 4
patients were lost due to instrument malfunction, as insufﬁ-
cient sample volume remained to allow a repeat analysis.
Table 1. Pharmacokinetic Characteristics of Intravenous Busulfan in Adults*
Height, Weight, IV Bu Dose, IV Bu Vc, IV Bu t1/2, IV Bu Cl, IV Bu AUC,
Patient Sex Age, y cm kg mg/kg L/kg h mL/min per kg µmol/L per min
1 F 37 168 104 0.08 0.05 0.6 0.94 345
2 M 55 180.3 75.9 0.08 0.21 6.5 1.92 168
7 F 45 165 65.5 0.20 0.90 2.9 3.54 229
10 M 50 152 70 0.40 0.64 6.1 2.57 632
11 F 53 172 65.4 0.40 0.28 3.8 2.14 765
12 M 46 180.3 89 0.80 0.22 3.6 3.37 964
13 M 19 183 85 0.80 0.25 5.6 2.87 1132
14 M 25 178 95 0.80 0.52 3.8 2.60 1250
16 M 50 188 81 0.80 0.37 3.8 2.18 1547
17 M 58 150 74.5 0.80 1.00 4.0 3.10 1051
Mean 43.8 171.7 80.5 0.52 0.44 4.1 2.5 1189†
Median 48 175 78.5 0.60 0.33 3.8 2.6 1132†
Range 19-58 150-188 65.4-104 0.08-0.80 0.05-1 0.6-6.5 0.94-3.54 964-1547†
SD 0.31 1.7 0.78 226†
Coefficient of variation, % 71 41.5 31.2 19†
*IV indicates intravenous; Bu, busulfan; Vc, central volume; Cl, total clearance normalized to actual body weight; AUC, calculated area under
the concentration-time curve. 
†Data from patients receiving intravenous busulfan dose level of 0.80 mg/kg.
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A complete PK proﬁle was obtained from 5 of 6 patients
at the highest IV Bu dose level (0.8 mg/kg). The median t1/2
was 3.8 hours (range, 0.6-6.5 hours) with IV Bu compared
with 1.8 hours (range, 0.6-2.3 hours) after oral drug. Total
Bu plasma clearance after IV Bu was 2.6 mL/min per kg
(range, 0.94-3.54 mL/min per kg), similar to the apparent
clearance after oral administration (3.4 mL/min per kg;
range, 2.1-8.1 mL/min per kg). The IV Bu consistently
yielded plasma AUC proﬁles (mean 1189 µmol/L per min;
range, 964-1547 µmol/L per min) similar to those observed
after oral drug (mean of 1135 µmol/L per min; range, 461-
1933 µmol/L per min), but with much less interpatient vari-
ation (Tables 1 and 2). The bioavailability of oral Bu was
highly variable among individuals (Table 2), in spite of our
attempts to standardize the delivery of oral drug (fasting,
consistent schedule, attempted control of nausea/vomiting).
Even though the bioavailability after oral dosing averaged
69%, the coefﬁcient of variation was >40%, and 2 of the 10
evaluable patients absorbed <15% of the given dose.
An example of the predictable plasma concentration ver-
sus time curve obtained using the IV formulation is demon-
strated in the Figure. The oral data from the same patient
(number 10) demonstrated the often unpredictable delay in
absorption and a varied and discontinuous absorption,
which resulted in a biphasic plasma concentration pattern
during this dosing interval.
DISCUSSION
The wide variability in both interpatient and intrapatient
Bu bioavailability after oral administration has hampered the
effectiveness of Bu-based high-dose pretransplantation con-
ditioning therapy. Slattery and colleagues [20,21] reported
that a suboptimal Bu exposure dose after oral BuCy2
increased the risk for both graft rejection and recurrent
leukemia after allogeneic HPCT. Further, a high-exposure
dose correlated with an increased risk for serious side effects
in the CNS and with an increased incidence of hepatic VOD
[6,16-19]. Finally, both Vassal et al. [13] and Hassan and col-
leagues [14,15] demonstrated that the generally overlooked
interdose variations in bioavailability after oral dosing may
be signiﬁcant and may contribute to the substantial variabil-
ity observed in toxicity and response, even when the dose is
adjusted based on PK measurements after the earliest doses.
An IV formulation would avoid such complications associ-
ated with oral drug administration, and in fact, this dosage
form minimized the observed interpatient variability charac-
teristics of the oral preparation to those that are the conse-
quences of individual differences in metabolic drug handling.
This result is reﬂected by the 19% coefﬁcient of variation of
AUC after IV dosing versus 37% after oral dosing. When we
used the IV Bu formulation as the reference point for PK
calculations, the bioavailability of oral drug in the present
study was estimated to average 69%, conﬁrming the previous
estimates in the range of 60% to 80% made after delivery of
low doses of IV and oral Bu [14] and after administration of
higher-dose oral and IV Bu in pretransplantation therapy
using a dimethyl sulfoxide (DMSO)-based formulation [33].
Although the average bioavailability of oral Bu in the current
study was 69%, the range was surprisingly high, varying
more than 10-fold from the lowest (F < 10%) to the highest
(F = 100%) subject, with 2 of the 10 evaluable patients hav-
ing <15% bioavailability of oral drug. The fact that 1 patient
was pharmacokinetically inevaluable due to drug loss
through vomiting highlights a major problem associated with
the oral formulation. Together with the erratic absorption
inherent in the oral preparation, loss of drug through emesis
becomes the single largest impediment to PK-guided dose
individualization of high-dose Bu.
In the current study, we found no acute side effects that
could be attributed to the solvent system. Thus, the new IV
Bu formulation is appropriate for administration in continued
human clinical trials. The decision to use a cosolvent system
of DMA and PEG-400 was based on several considerations;
Table 2. Pharmacokinetic Characteristics of Oral Busulfan in Adults*
Height, Weight, Oral Bu Dose, Oral Bu Vc, Oral Bu Oral Bu Cl, Oral Bu AUC, Bioavailability, 
Patient Sex Age, y cm kg mg/kg L/kg t1/2, hours mL/min per kg µmol/L per min %
1 F 37 168 104 1.0 0.67 0.94 8.1 461 10.8
2 M 55 180.3 75.9 1.0 0.11 0.60 2.1 1409 68
7 F 45 165 65.5 1.0 0.22 0.75 3.4 1195 94
10 M 50 152 70 1.0 0.86 2.24 4.5 915 58
11 F 53 172 65.4 1.0 0.99 1.6 4.0 1001 52
12 M 46 180.3 89 1.0 0.89 1.9 5.5 735 61
13 M 19 183 85 1.0 † † † † <10†
14 M 25 178 95 1.0 0.54 2.3 2.7 1329 85
16 M 50 188 81 1.0 0.33 1.8 2.2 1933 100
17 M 58 150 74.5 1.0 0.46 2.1 2.6 1234 94
Mean 43.8 171.7 80.5 1.0 0.56 1.58 3.9 1135 69.2
Median 48 175 78.5 1.0 0.54 1.80 3.4 1195 68
Range 19-58 150-188 65.4-104 1.0-1.0 0.11-0.99 0.6-2.3 2.1-8.1 461-1933 10.8-100
SD 0.0 0.31 0.66 1.94 425 28
Coefficient of variation, % 0.0 55.4 41.5 49.7 37.4 40.5
*Percentage bioavailability was calculated as (AUCoral/AUCIV)  100 and the AUCIV was normalized to a dose of 1 mg/kg. Bu indicates busulfan;
Vc, central volume; Cl, apparent total clearance normalized to actual body weight; AUC, calculated area under the concentration-time curve. 
†Busulfan was detectable but below the limits of quantiﬁcation for this oral dose.
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there is extensive experience with the pharmaceutical use of
both DMA and PEG-400 as the basis for a composite solvent
system for anticancer agents. For example, both the investi-
gational agent m-AMSA and (the commercially available)
teniposide (Vumon) use DMA-based formulations [34,35],
and (the commercially available) L-asparaginase [36] and
-interferon [37] pharmaceutical formulations use PEG or
PEG-400 [38] as a cosolvent or a covalent-bound carrier.
Additionally, DMA is an excellent solvent for Bu [23,24].
Further, DMA is in itself a potent inducer of myeloid cell
differentiation; in this aspect, it is at least 25-fold more
potent than DMSO [39]. Finally, DMA has in itself shown
activity as an anticancer agent when it was tested in an NCI-
sponsored phase 1 trial [40]. In the NCI trial, the dose-lim-
iting toxicities of DMA were reported as mild, transient
impairment of liver function and reversible confusion and
stupor; in a few patients, delayed visual and auditory
hallucinations appeared at doses exceeding 400 mg/kg daily
for 5 days. The maximum total DMA dose of the present Bu
formulation if used in an IV Bu-based myeloablative regi-
men (BuCy2) in an adult patient can be calculated to be
about 40% of that reported as necessary to result in adverse
effects when DMA was administered as a single agent [41].
By comparison, when teniposide was used in dose-intensive
chemotherapy, the delivered DMA dose approached or
often exceeded the dose that would be achieved if the cur-
rent (Busulfex) formulation were used in a myeloablative
regimen (deduced from [41-43]).
The most serious adverse events reported after dose-
intensive therapy with teniposide have been myelosuppres-
sion and mucositis. Only 1 report described CNS events
such as somnolence, hypotension, and stupor, in 3 pediatric
patients who received teniposide as a 4-hour infusion at a
dose of >600 mg/m2 [44]. These authors concluded, how-
ever, that the most likely reason for CNS depression in their
patients was the high ethanol content in the teniposide for-
mulation [44], which in combination with a high infusion
rate yielded high, toxic ethanol concentrations in the CNS
[44,45]. When teniposide was administered as a prolonged,
continuous infusion over 72 hours in dose-intensive regi-
mens (>750 mg/m2, repeated every 4-5 weeks), no serious
adverse CNS events were encountered [46]. As for the uses
of PEG-400 in the formulation, this was used as a cosolvent
to stabilize the Bu in solution and make it possible to dilute
it with normal saline or D5W without precipitation of Bu in
the infusate. Based on the literature, no serious adverse
effects should be expected in the dose range of PEG-400
achieved in an IV Bu-based conditioning program.
Based on the PK parameters obtained for Bu after oral
versus IV administration in this study, we think that an
appropriate starting dose of IV Bu for our forthcoming
phase 2 study would be 0.8 mg/kg per dose, given the
observed median IV Bu plasma clearance of approximately
2.6 mL/min per kg and the mean AUC of 1189 µmol/L per
minute as listed in Table 1. This assumes that if we retain
the BuCy2 schedule of the present study, the repetitive
0.8 mg/kg dose should result in a mean AUC in the study
population of approximately 1100-1200 µmol/L per minute,
well below the AUC of 1500 µmol/L per minute that has
previously been associated with an increased risk for VOD
[18]. This target AUC should be sufficient to assure
engraftment and secure a pronounced antileukemic effect,
yet reduce the risk for serious VOD and CNS toxicity. It
should be recognized, however, that the suggested IV Bu
dose of 0.8 mg/kg as appropriate for a phase 2 trial is based
on a limited amount of PK information, because there was
no alternative commercially available IV product available
for comparative PK studies, and very limited information
exists about the metabolic disposition of IV-administered
Bu. However, our reported median plasma clearance after
Plasma busulfan concentration (Conc) versus time plots for busulfan after administration of intravenous (IV) drug and oral drug, respectively, from
patient number 10. Derived pharmacokinetic parameters were used to simulate the oral data, such that comparable plasma concentration-time
curves could be represented under non–steady-state conditions after both IV and oral dosing. Data were normalized to a dose of 1.0 mg/kg. 
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IV Bu is similar to that reported by Hassan et al. [14] in a
limited trial of low-dose IV Bu in a complex formulation
system in adults (2.6 versus 2.49 mL/min per kg) and that of
Schuler et al. [33] using a DMSO-Bu formulation. Thus,
our preferred dose of 0.8 mg/kg in the modiﬁed BuCy2 reg-
imen should be considered only a starting dose for a phase 2
study; the deﬁnitive IV Bu dose for myeloablative regimens
may later be modified to account for any changes in the
side-effect profile when the total Bu dose is administered
parenterally. The optimal infusion time and administration
schedule have yet to be determined for IV Bu, but the
2-hour infusion resulted in a Tmax that was similar to that
observed after the oral drug (2.0 hours for IV versus 1.8 hours
for the oral formulation). Additionally, the similarity of the
mean t1/2 and clearance measurements after IV Bu in this
study to those reported in several previous studies of oral Bu
suggest that the solvent system did not inﬂuence Bu metabo-
lism. However, it should be conﬁrmed that repeated IV doses
do not signiﬁcantly alter the Bu PK proﬁle compared with
the oral Bu preparation.
Further clinical studies using this IV Bu formulation are
warranted. The parenteral route of Bu administration will
assure complete bioavailability with more predictable blood
levels via controlled infusion and lessen the risks for seri-
ous/life-threatening toxicity as well as (possibly) lowering
the risks for graft rejection and recurrent leukemia after
transplantation.
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